Each non-voting ordinary share of Grifols represents two listed ADRs. The ticker symbol is GRFS.
Grifols is a Spanish holding company specializing in the pharmaceutical-hospital sector and is present in more than 90 countries.
Since 2006, the company has been listed on the Spanish Stock Exchange. The Level III ADR program has been launched in conjunction with Grifols’ recent acquisition of Talecris Biotherapeutics.
Deutsche Bank also serves as depositary for Grifols’ unlisted Level I ADR program relating to the company’s Class A voting shares.
Deutsche Bank head of global equity services Akbar Poonawala said the bank congratulate Grifols on its important acquisition in the US and its ADR listing on NASDAQ. The bank will continue to provide a broad range of customized services to enhance Grifols’ IR strategies and shareholder base.
